{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:28Z","timestamp":1791976108660,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["RTI2018-094130-B-100"],"award-info":[{"award-number":["RTI2018-094130-B-100"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MINECO\/FEDER","award":["PID2021-124632OB-100"],"award-info":[{"award-number":["PID2021-124632OB-100"]}]},{"name":"Next generation EU funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13402-024-01005-w","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T14:03:39Z","timestamp":1729519419000},"page":"437-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SUMOylation regulates the aggressiveness of breast cancer-associated fibroblasts"],"prefix":"10.1007","volume":"48","author":[{"given":"Angelica","family":"Mart\u00ednez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mendiburu-Eli\u00e7abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Machuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga M.","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Luque-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Castillo-Lluva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"1240115","DOI":"10.3389\/fonc.2023.1240115","volume":"13","author":"H. Dutta","year":"2023","unstructured":"H. Dutta, N. Jain, Post-translational modifications and their implications in cancer. Front. Oncol. 13, 1240115 (2023)","journal-title":"Front. Oncol."},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.mam.2022.101097","volume":"86","author":"S. Pan","year":"2022","unstructured":"S. Pan, R. Chen, Pathological implication of protein post-translational modifications in cancer. Mol. Aspects Med. 86, 101097 (2022)","journal-title":"Mol. Aspects Med."},{"issue":"2","key":"1005_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1042\/BJ20100158","volume":"428","author":"K.A. Wilkinson","year":"2010","unstructured":"K.A. Wilkinson, J.M. Henley, Mechanisms, regulation and consequences of protein SUMOylation. Biochem. J. 428(2), 133\u2013145 (2010)","journal-title":"Biochem. J."},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"26509","DOI":"10.1038\/srep26509","volume":"6","author":"Y.C. Liang","year":"2016","unstructured":"Y.C. Liang, et al., SUMO5, a novel poly-SUMO isoform, regulates PML nuclear bodies. Sci. Rep. 6, 26509 (2016)","journal-title":"Sci. Rep."},{"issue":"3","key":"1005_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0092-8674(02)00630-X","volume":"108","author":"V. Bernier-Villamor","year":"2002","unstructured":"V. Bernier-Villamor, et al., Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108(3), 345\u2013356 (2002)","journal-title":"Cell"},{"issue":"1","key":"1005_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/bmc-2016-0030","volume":"8","author":"A. Pichler","year":"2017","unstructured":"A. Pichler, et al., SUMO conjugation - a mechanistic view. Biomol. Concepts 8(1), 13\u201336 (2017)","journal-title":"Biomol. Concepts"},{"issue":"4","key":"1005_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","volume":"100","author":"H.M. Chang","year":"2020","unstructured":"H.M. Chang, E.T.H. Yeh, SUMO: from bench to bedside. Physiol. Rev. 100(4), 1599\u20131619 (2020)","journal-title":"Physiol. Rev."},{"issue":"11","key":"1005_CR8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3390\/cells10112825","volume":"10","author":"T.Y. Yau","year":"2021","unstructured":"T.Y. Yau, et al., SUMO interacting motifs: structure and function. Cells. 10(11), 2825 (2021)","journal-title":"Cells"},{"issue":"7","key":"1005_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41388-018-0468-9","volume":"38","author":"T. Traboulsi","year":"2019","unstructured":"T. Traboulsi, et al., Role of SUMOylation in differential ERalpha transcriptional repression by tamoxifen and fulvestrant in breast cancer cells. Oncogene 38(7), 1019\u20131037 (2019)","journal-title":"Oncogene"},{"issue":"1","key":"1005_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41523-024-00644-4","volume":"10","author":"R.T. Powell","year":"2024","unstructured":"R.T. Powell, et al., Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer. NPJ Breast Cancer 10(1), 37 (2024)","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"1005_CR11","doi-asserted-by":"publisher","first-page":"jcs234120","DOI":"10.1242\/jcs.234120","volume":"132","author":"M. Lorente","year":"2019","unstructured":"M. Lorente, et al., Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1. J. Cell Sci. 132(20), jcs234120 (2019)","journal-title":"J. Cell Sci."},{"issue":"2","key":"1005_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.yexcr.2018.07.005","volume":"370","author":"Z. Huang","year":"2018","unstructured":"Z. Huang, et al., Talin is a substrate for SUMOylation in migrating cancer cells. Exp. Cell Res. 370(2), 417\u2013425 (2018)","journal-title":"Exp. Cell Res."},{"issue":"9","key":"1005_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.5732\/cjc.011.10084","volume":"30","author":"S.F. Chen","year":"2011","unstructured":"S.F. Chen, et al., Ubc9 expression predicts chemoresistance in breast cancer. Chin. J. Cancer 30(9), 638\u2013644 (2011)","journal-title":"Chin. J. Cancer"},{"issue":"9","key":"1005_CR14","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1021\/pr500119a","volume":"13","author":"D. Subramonian","year":"2014","unstructured":"D. Subramonian, et al., Analysis of changes in SUMO-2\/3 modification during breast cancer progression and metastasis. J. Proteome Res. 13(9), 3905\u20133918 (2014)","journal-title":"J. Proteome Res."},{"issue":"6797","key":"1005_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"C.M. Perou","year":"2000","unstructured":"C.M. Perou, et al., Molecular portraits of human breast tumours. Nature 406(6797), 747\u2013752 (2000)","journal-title":"Nature"},{"issue":"19","key":"1005_CR16","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T. Sorlie","year":"2001","unstructured":"T. Sorlie, et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98(19), 10869\u201310874 (2001)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1005_CR17","doi-asserted-by":"crossref","unstructured":"E. Orrantia-Borunda, et al., In: Subtypes of Breast Cancer, ed. by H.N. Mayrovitz. Breast Cancer (Brisbane (AU), 2022)","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"28","key":"1005_CR18","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1200\/JCO.2008.21.7075","volume":"27","author":"E.K. Millar","year":"2009","unstructured":"E.K. Millar, et al., Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J. Clin. Oncol. 27(28), 4701\u20134708 (2009)","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"1005_CR19","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"B.G. Haffty","year":"2006","unstructured":"B.G. Haffty, et al., Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24(36), 5652\u20135657 (2006)","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"1005_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","volume":"26","author":"M. Kyndi","year":"2008","unstructured":"M. Kyndi, et al., Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 26(9), 1419\u20131426 (2008)","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"1005_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00441-016-2471-1","volume":"365","author":"Y. Mezawa","year":"2016","unstructured":"Y. Mezawa, A. Orimo, The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas. Cell Tissue Res. 365(3), 675\u2013689 (2016)","journal-title":"Cell Tissue Res."},{"issue":"16","key":"1005_CR22","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"N.M. Anderson","year":"2020","unstructured":"N.M. Anderson, M.C. Simon, The tumor microenvironment. Curr. Biol. 30(16), R921\u2013R925 (2020)","journal-title":"Curr. Biol."},{"issue":"Suppl 2","key":"1005_CR23","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.breast.2013.07.010","volume":"22","author":"R.E. Coleman","year":"2013","unstructured":"R.E. Coleman, et al., The metastatic microenvironment of breast cancer: clinical implications. Breast 22(Suppl 2), S50\u20136 (2013)","journal-title":"Breast"},{"issue":"6","key":"1005_CR24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/cancers13061399","volume":"13","author":"R.S. Joshi","year":"2021","unstructured":"R.S. Joshi, et al., The role of cancer-associated fibroblasts in tumor progression. Cancers (Basel). 13(6), 1399 (2021)","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1005_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R. Kalluri","year":"2006","unstructured":"R. Kalluri, M. Zeisberg, Fibroblasts in cancer. Nat. Rev. Cancer. 6(5), 392\u2013401 (2006)","journal-title":"Nat. Rev. Cancer"},{"key":"1005_CR26","doi-asserted-by":"publisher","first-page":"1333839","DOI":"10.3389\/fonc.2023.1333839","volume":"13","author":"J. Zheng","year":"2023","unstructured":"J. Zheng, H. Hao, The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer. Front. Oncol. 13, 1333839 (2023)","journal-title":"Front. Oncol."},{"issue":"16","key":"1005_CR27","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L. Jenkins","year":"2022","unstructured":"L. Jenkins, et al., Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 82(16), 2904\u20132917 (2022)","journal-title":"Cancer Res."},{"issue":"10","key":"1005_CR28","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/cells8101133","volume":"8","author":"M. Olea-Flores","year":"2019","unstructured":"M. Olea-Flores, et al., Leptin promotes expression of EMT-related transcription factors and invasion in a Src and FAK-dependent pathway in MCF10A mammary epithelial cells. Cells. 8(10), 1133 (2019)","journal-title":"Cells"},{"issue":"1-2","key":"1005_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y. Hu","year":"2009","unstructured":"Y. Hu, G.K. Smyth, ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods. 347(1-2), 70\u201378 (2009)","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"1005_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)81478-6","volume":"94","author":"J. Kim","year":"1998","unstructured":"J. Kim, et al., Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94(3), 353\u2013362 (1998)","journal-title":"Cell"},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2021.08.014","volume":"521","author":"A. Martinez-Lopez","year":"2021","unstructured":"A. Martinez-Lopez, et al., Inhibition of RAC1 activity in cancer associated fibroblasts favours breast tumour development through IL-1beta upregulation. Cancer Lett. 521, 14\u201328 (2021)","journal-title":"Cancer Lett."},{"issue":"6","key":"1005_CR32","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-19-0353","volume":"26","author":"P. Fernandez-Nogueira","year":"2020","unstructured":"P. Fernandez-Nogueira, et al., Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clin. Cancer. Res. 26(6), 1432\u20131448 (2020)","journal-title":"Clin. Cancer. Res."},{"issue":"46","key":"1005_CR33","doi-asserted-by":"publisher","first-page":"20009","DOI":"10.1073\/pnas.1013805107","volume":"107","author":"Y. Kojima","year":"2010","unstructured":"Y. Kojima, et al., Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. U. S. A. 107(46), 20009\u201320014 (2010)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"1005_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chembiol.2009.01.009","volume":"16","author":"I. Fukuda","year":"2009","unstructured":"I. Fukuda, et al., Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 16(2), 133\u2013140 (2009)","journal-title":"Chem. Biol."},{"issue":"1","key":"1005_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K. Kessenbrock","year":"2010","unstructured":"K. Kessenbrock, V. Plaks, Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141(1), 52\u201367 (2010)","journal-title":"Cell"},{"issue":"5","key":"1005_CR36","first-page":"5831","volume":"14","author":"L. Qiao","year":"2017","unstructured":"L. Qiao, et al., Ginkgolic acid inhibits the invasiveness of colon cancer cells through AMPK activation. Oncol. Lett. 14(5), 5831\u20135838 (2017)","journal-title":"Oncol. Lett."},{"issue":"1","key":"1005_CR37","first-page":"1021","volume":"15","author":"J. Liu","year":"2018","unstructured":"J. Liu, et al., Effects of ginkgol C17:1 on cisplatin-induced autophagy and apoptosis in HepG2 cells. Oncol. Lett. 15(1), 1021\u20131029 (2018)","journal-title":"Oncol. Lett."},{"issue":"1","key":"1005_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(01)01237-7","volume":"430","author":"B. Ahlemeyer","year":"2001","unstructured":"B. Ahlemeyer, et al., Ginkgolic acids induce neuronal death and activate protein phosphatase type-2C. Eur. J. Pharmacol. 430(1), 1\u20137 (2001)","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"1005_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pro.4218","volume":"31","author":"P.D. Thomas","year":"2022","unstructured":"P.D. Thomas, et al., PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci. 31(1), 8\u201322 (2022)","journal-title":"Protein Sci."},{"key":"1005_CR40","doi-asserted-by":"publisher","first-page":"115425","DOI":"10.1016\/j.biopha.2023.115425","volume":"166","author":"Z. Zhao","year":"2023","unstructured":"Z. Zhao, et al., Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance. Biomed. Pharmacother. 166, 115425 (2023)","journal-title":"Biomed. Pharmacother."},{"issue":"14","key":"1005_CR41","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers13143466","volume":"13","author":"I. Belhabib","year":"2021","unstructured":"I. Belhabib, et al., Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy? Cancers (Basel). 13(14), 3466 (2021)","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1005_CR42","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/ncb2112","volume":"12","author":"S. Castillo-Lluva","year":"2010","unstructured":"S. Castillo-Lluva, et al., SUMOylation of the GTPase Rac1 is required for optimal cell migration. Nat. Cell Biol. 12(11), 1078\u20131085 (2010)","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"1005_CR43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.emboj.7601518","volume":"26","author":"J.P. ten Klooster","year":"2007","unstructured":"J.P. ten Klooster, et al., Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J. 26(2), 336\u2013345 (2007)","journal-title":"EMBO J."},{"issue":"7","key":"1005_CR44","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/molecules28072976","volume":"28","author":"N. Ma","year":"2023","unstructured":"N. Ma, et al., Rac1: a regulator of cell migration and a potential target for cancer therapy. Molecules. 28(7), 2976 (2023)","journal-title":"Molecules"},{"key":"1005_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/msb4100094","volume":"2","author":"A. Wolf-Yadlin","year":"2006","unstructured":"A. Wolf-Yadlin, et al., Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst. Biol. 2, 54 (2006)","journal-title":"Mol. Syst. Biol."},{"issue":"17","key":"1005_CR46","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","volume":"11","author":"Z. Li","year":"2021","unstructured":"Z. Li, C. Sun, Z. Qin, Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 11(17), 8322\u20138336 (2021)","journal-title":"Theranostics"},{"issue":"8","key":"1005_CR47","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.celrep.2015.02.006","volume":"10","author":"D. Zhang","year":"2015","unstructured":"D. Zhang, et al., Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation. Cell Rep. 10(8), 1335\u20131348 (2015)","journal-title":"Cell Rep."},{"key":"1005_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-030-65768-0_14","volume":"1311","author":"C. Sazeides","year":"2021","unstructured":"C. Sazeides, A. Le, Metabolic relationship between cancer-associated fibroblasts and cancer cells. Adv. Exp. Med. Biol. 1311, 189\u2013204 (2021)","journal-title":"Adv. Exp. Med. Biol."},{"issue":"7","key":"1005_CR49","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1007\/s13277-015-4629-y","volume":"37","author":"E. Bagordakis","year":"2016","unstructured":"E. Bagordakis, et al., Secretome profiling of oral squamous cell carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures. Tumour Biol. 37(7), 9045\u20139057 (2016)","journal-title":"Tumour Biol."},{"issue":"5","key":"1005_CR50","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.cell.2020.10.045","volume":"183","author":"L. Jiang","year":"2020","unstructured":"L. Jiang, et al., Direct tumor killing and immunotherapy through anti-SerpinB9 therapy. Cell 183(5), 1219\u20131233e18 (2020)","journal-title":"Cell"},{"issue":"5","key":"1005_CR51","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M. Valiente","year":"2014","unstructured":"M. Valiente, et al., Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156(5), 1002\u20131016 (2014)","journal-title":"Cell"},{"issue":"5","key":"1005_CR52","first-page":"1875","volume":"44","author":"Q. Zhang","year":"2020","unstructured":"Q. Zhang, L. Lei, D. Jing, Knockdown of SERPINE1 reverses resistance of triple\u2011negative breast cancer to paclitaxel via suppression of VEGFA. Oncol. Rep. 44(5), 1875\u20131884 (2020)","journal-title":"Oncol. Rep."},{"issue":"3","key":"1005_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cbin.12126","volume":"48","author":"X. Zhou","year":"2024","unstructured":"X. Zhou, et al., THBS1 promotes angiogenesis and accelerates ESCC malignant progression by the HIF-1\/VEGF signaling pathway. Cell Biol. Int. 48(3), 311\u2013324 (2024)","journal-title":"Cell Biol. Int."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-01005-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-024-01005-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-01005-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T09:02:58Z","timestamp":1744621378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-024-01005-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s13402-024-01005-w","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"7 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ascites effusions were collected by the Manchester Cancer Research Centre (MCRC) Biobank (ethical approval: 12-ROCL-01). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}